Deflazacort in giant cell arteritis [6]

Journal of Rheumatology

Volumn 29, Issue 10, 2002, Pages 2244-2245

  Devogelaer, Jean Pierre ^a   Gennari, Carlo ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; DEFLAZACORT; PREDNISONE; VITAMIN D;

BONE ATROPHY; BONE MASS; BONE METABOLISM; DRUG EFFECT; ERYTHROCYTE SEDIMENTATION RATE; GIANT CELL ARTERITIS; HUMAN; LETTER; PRIORITY JOURNAL; RANDOMIZATION; RHEUMATIC POLYMYALGIA; VISUAL IMPAIRMENT; VITAMIN SUPPLEMENTATION;

ANTI-INFLAMMATORY AGENTS; BONE DENSITY; BONE DISEASES, METABOLIC; CALCIFEDIOL; DIETARY SUPPLEMENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PREDNISONE; PREGNENEDIONES; RANDOMIZED CONTROLLED TRIALS; TEMPORAL ARTERITIS;

EID: 0036791846     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (8)

1. Cacoub P, Chemlal K, Khalifa P, et al. Deflazacort versus prednisone in patients with giant cell arteritis: effects on bone mass loss. J Rheumatol 2001;28:2474-9.
2. Devogelaer JP, Huaux JP, Dufour JP, Esselinckx W, Stasse P, Nagant de Deuxchaisnes C. Bone-sparing action of deflazacort versus equipotent doses of prednisone: a double-blind study in males with rheumatoid arthritis. In: Christiansen C, Johansen JS, Riis BJ, editors. Osteoporosis. Viborg: Norhaven A/S; 1987:1014-5.
3. Gennari C, Imbimbo B. Effects of prednisone and deflazacort on vertebral bone mass. Calcif Tissue Int 1985;37:592-3.
4. Olgaard K, Storm T, van Wovern N, et al. Glucocorticoid-induced osteoporosis in the lumbar spine, forearm, and mandible of nephrotic patients: a double-blind study on the high-dose, long-term effects of prednisone versus deflazacort. Calcif Tissue Int 1992;50:490-7.
5. Lippuner K, Casez J, Horber F, Jaeger P. Effects of deflazacort versus prednisone on bone mass, body composition and lipid profile. A randomized double blind study in kidney transplant patients. J Clin Endocrinol Metab 1998;83:3795-802.
6. Hahn TJ, Halstead LR, Teitelbaum SL, Hahn BH. Altered mineral metabolism in glucocorticoid-induced osteopenia. Effect of 25- hydroxyvitamin D administration. J Clin Invest 1979;64:655-65.
7. Devogelaer JP, Esselinckx W, Nagant de Deuxchaisnes C. Calcidiol protects bone mass in rheumatoid arthritis treated by low dose glucocorticoids. In: Norman AW, Bouillon R, Thomasset M, editors. Vitamin D. A pluripotent steroid hormone: Structural studies, molecular endocrinology and clinical applications. Berlin: Walter de Gruyter; 1994:855-6.
8. Di Munno O, Beghe F, Favini P, et al. Prevention of glucocorticoid-induced osteoporosis effect on oral 25-hydroxyvitamin D and calcium. Clin Rheumatol 1989;8:202-7.